Can causality assessment fulfill the new European definition of adverse drug reaction?: A review of methods used in spontaneous reporting

A. Mascolo; C. Scavone; M. Sessa; G. di Mauro; D. Cimmaruta; V. Orlando; F. Rossi; L. Sportiello; A. Capuano

doi:10.1016/j.phrs.2017.07.005

Can causality assessment fulfill the new European definition of adverse drug reaction? A review of methods used in spontaneous reporting

A. Mascolo, C. Scavone, M. Sessa, G. di Mauro, D. Cimmaruta, V. Orlando, F. Rossi, L. Sportiello, A. Capuano

31 Citations (Scopus)

Abstract

Causality assessment is a fundamental biomedical technique for the signal detection performed by Pharmacovigilance centers in a Spontaneous reporting system. Moreover, it is a crucial and important practice for detecting preventable adverse drug reactions. Among different methods for causality assessment, algorithms (such as the Naranjo, or Begaud Methods) seem for their operational procedure and easier applicability one of the most commonly used methods. With the upcoming of the new European Pharmacovigilance legislation including in the definition of the adverse event also effects resulting from abuse, misuse and medication error, all well-known preventable causes of ADRs, there was an emerging need to evaluate whether algorithms could fulfill this new definition. In this review, twenty-two algorithmic methods were identified and none of them seemed to fulfill perfectly the new criteria of adverse event although some of them come close. In fact, several issues were arisen in applying causality assessment algorithms to these new definitions as for example the impossibility to answer the rechallenge question in case of medication error or AEFI (Adverse Event Following Immunization). Moreover, the exact conditions at which events occurred, as for example dosage or mode of administration should be considered to better assess causality in conditions of abuse/overdose, or misuse as well as in conditions of lack of expected efficacy reports for biotechnological drugs and adverse event occurring after mixing of vaccines. Therefore, this review highlights the need of updating algorithmic methods to allow a perfect applicability in all possible clinical scenarios accordingly or not with the terms of marketing authorization.

Original language	English
Journal	Pharmacological Research
Volume	123
Pages (from-to)	122-129
ISSN	1043-6618
DOIs	https://doi.org/10.1016/j.phrs.2017.07.005
Publication status	Published - Sept 2017
Externally published	Yes

Keywords

Adverse drug reaction reporting system
Adverse event definition
Algorithmic method
Causality assessment
Pharmacovigilance legislation

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.phrs.2017.07.005

Cite this

@article{cf0f26140ca0465a91399a99ad28caa4,

title = "Can causality assessment fulfill the new European definition of adverse drug reaction?: A review of methods used in spontaneous reporting",

abstract = "Causality assessment is a fundamental biomedical technique for the signal detection performed by Pharmacovigilance centers in a Spontaneous reporting system. Moreover, it is a crucial and important practice for detecting preventable adverse drug reactions. Among different methods for causality assessment, algorithms (such as the Naranjo, or Begaud Methods) seem for their operational procedure and easier applicability one of the most commonly used methods. With the upcoming of the new European Pharmacovigilance legislation including in the definition of the adverse event also effects resulting from abuse, misuse and medication error, all well-known preventable causes of ADRs, there was an emerging need to evaluate whether algorithms could fulfill this new definition. In this review, twenty-two algorithmic methods were identified and none of them seemed to fulfill perfectly the new criteria of adverse event although some of them come close. In fact, several issues were arisen in applying causality assessment algorithms to these new definitions as for example the impossibility to answer the rechallenge question in case of medication error or AEFI (Adverse Event Following Immunization). Moreover, the exact conditions at which events occurred, as for example dosage or mode of administration should be considered to better assess causality in conditions of abuse/overdose, or misuse as well as in conditions of lack of expected efficacy reports for biotechnological drugs and adverse event occurring after mixing of vaccines. Therefore, this review highlights the need of updating algorithmic methods to allow a perfect applicability in all possible clinical scenarios accordingly or not with the terms of marketing authorization.",

keywords = "Adverse drug reaction reporting system, Adverse event definition, Algorithmic method, Causality assessment, Pharmacovigilance legislation",

author = "A. Mascolo and C. Scavone and M. Sessa and {di Mauro}, G. and D. Cimmaruta and V. Orlando and F. Rossi and L. Sportiello and A. Capuano",

year = "2017",

month = sep,

doi = "10.1016/j.phrs.2017.07.005",

language = "English",

volume = "123",

pages = "122--129",

journal = "Pharmacological Research",

issn = "1043-6618",

publisher = "Academic Press",

}

TY - JOUR

T1 - Can causality assessment fulfill the new European definition of adverse drug reaction?

T2 - A review of methods used in spontaneous reporting

AU - Mascolo, A.

AU - Scavone, C.

AU - Sessa, M.

AU - di Mauro, G.

AU - Cimmaruta, D.

AU - Orlando, V.

AU - Rossi, F.

AU - Sportiello, L.

AU - Capuano, A.

PY - 2017/9

Y1 - 2017/9

N2 - Causality assessment is a fundamental biomedical technique for the signal detection performed by Pharmacovigilance centers in a Spontaneous reporting system. Moreover, it is a crucial and important practice for detecting preventable adverse drug reactions. Among different methods for causality assessment, algorithms (such as the Naranjo, or Begaud Methods) seem for their operational procedure and easier applicability one of the most commonly used methods. With the upcoming of the new European Pharmacovigilance legislation including in the definition of the adverse event also effects resulting from abuse, misuse and medication error, all well-known preventable causes of ADRs, there was an emerging need to evaluate whether algorithms could fulfill this new definition. In this review, twenty-two algorithmic methods were identified and none of them seemed to fulfill perfectly the new criteria of adverse event although some of them come close. In fact, several issues were arisen in applying causality assessment algorithms to these new definitions as for example the impossibility to answer the rechallenge question in case of medication error or AEFI (Adverse Event Following Immunization). Moreover, the exact conditions at which events occurred, as for example dosage or mode of administration should be considered to better assess causality in conditions of abuse/overdose, or misuse as well as in conditions of lack of expected efficacy reports for biotechnological drugs and adverse event occurring after mixing of vaccines. Therefore, this review highlights the need of updating algorithmic methods to allow a perfect applicability in all possible clinical scenarios accordingly or not with the terms of marketing authorization.

AB - Causality assessment is a fundamental biomedical technique for the signal detection performed by Pharmacovigilance centers in a Spontaneous reporting system. Moreover, it is a crucial and important practice for detecting preventable adverse drug reactions. Among different methods for causality assessment, algorithms (such as the Naranjo, or Begaud Methods) seem for their operational procedure and easier applicability one of the most commonly used methods. With the upcoming of the new European Pharmacovigilance legislation including in the definition of the adverse event also effects resulting from abuse, misuse and medication error, all well-known preventable causes of ADRs, there was an emerging need to evaluate whether algorithms could fulfill this new definition. In this review, twenty-two algorithmic methods were identified and none of them seemed to fulfill perfectly the new criteria of adverse event although some of them come close. In fact, several issues were arisen in applying causality assessment algorithms to these new definitions as for example the impossibility to answer the rechallenge question in case of medication error or AEFI (Adverse Event Following Immunization). Moreover, the exact conditions at which events occurred, as for example dosage or mode of administration should be considered to better assess causality in conditions of abuse/overdose, or misuse as well as in conditions of lack of expected efficacy reports for biotechnological drugs and adverse event occurring after mixing of vaccines. Therefore, this review highlights the need of updating algorithmic methods to allow a perfect applicability in all possible clinical scenarios accordingly or not with the terms of marketing authorization.

KW - Adverse drug reaction reporting system

KW - Adverse event definition

KW - Algorithmic method

KW - Causality assessment

KW - Pharmacovigilance legislation

U2 - 10.1016/j.phrs.2017.07.005

DO - 10.1016/j.phrs.2017.07.005

M3 - Review

C2 - 28694146

SN - 1043-6618

VL - 123

SP - 122

EP - 129

JO - Pharmacological Research

JF - Pharmacological Research

ER -